Free tool
FAERS Monitor: Zoladex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020578 or its brand name (Zoladex, Goserelin Acetate). Reports on generic versions are filed under their own applications.
Reports
13,568
Serious
12,237
90% of reports
Hospitalization
3,988
Death reported
2,422
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,594
- malignant neoplasm progression1,367
- fatigue925
- metastases to bone706
- neutropenia680
- nausea624
- asthenia540
- hot flush527
- diarrhoea521
- off label use493
- pain492
- arthralgia457
- metastases to liver451
- dyspnoea449
- headache418
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 218 |
| 2006 | 246 |
| 2007 | 274 |
| 2008 | 296 |
| 2009 | 298 |
| 2010 | 265 |
| 2011 | 385 |
| 2012 | 485 |
| 2013 | 405 |
| 2014 | 446 |
| 2015 | 589 |
| 2016 | 571 |
| 2017 | 485 |
| 2018 | 691 |
| 2019 | 777 |
| 2020 | 902 |
| 2021 | 1,190 |
| 2022 | 1,030 |
| 2023 | 1,255 |
| 2024 | 1,020 |
| 2025 | 836 |
| 2026 | 680 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,591 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metastases to boneSignal | 706 | 69.6 | 64.7 | 45,673 |
| metastases to liverSignal | 451 | 40.8 | 37.2 | 17,045 |
| malignant neoplasm progressionSignal | 1,367 | 21.0 | 19.9 | 25,741 |
| hot flushSignal | 527 | 10.9 | 10.0 | 4,717 |
| neutropeniaSignal | 680 | 7.8 | 7.2 | 4,021 |
| deathSignal | 1,594 | 2.9 | 2.7 | 2,022 |
| astheniaSignal | 540 | 2.2 | 2.1 | 370 |
| fatigue | 925 | 1.8 | 1.7 | 369 |
| arthralgia | 457 | 1.7 | 1.6 | 135 |
| diarrhoea | 521 | 1.3 | 1.2 | 27 |
| pain | 492 | 1.2 | 1.1 | 24 |
| dyspnoea | 449 | 1.2 | 1.1 | 20 |
| nausea | 624 | 1.2 | 1.1 | 26 |
| headache | 418 | 1.0 | 0.9 | 0 |
| off label use | 493 | 0.9 | 0.8 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.